The Prescribing Clinician Made the Mistake
The prescribing clinician who ordered the SGLT2 inhibitor is responsible for this error, as they failed to perform the mandatory pre-prescription assessment required by current guidelines. 1
Required Pre-Prescription Assessment
Before prescribing any SGLT2 inhibitor, clinicians must systematically evaluate four critical domains 1:
1. Renal Function Assessment
- Measure or estimate glomerular filtration rate (GFR)
- Current guidelines support SGLT2i use down to eGFR ≥20 mL/min/1.73 m² 1
- An initial eGFR decline at 6 months is expected and not a contraindication 2
- Failure to check renal function represents a fundamental prescribing error
2. Albuminuria Status
- Measure urine albumin-to-creatinine ratio (ACR)
- Risk stratification requires knowing the degree of albuminuria 1
- Note: SGLT2i-associated glucosuria can increase Jaffé-based uACR by ~8.5%, though this rarely changes clinical management 2
- Prescribing without albuminuria assessment prevents proper risk stratification
3. Infection Risk Evaluation
- Screen for history of recurrent urinary tract infections 3
- Assess for history of mycotic (fungal) infections, particularly genital 3
- These are the most common adverse effects requiring monitoring 4
- Infection history is a documented prescriber concern that must be addressed pre-prescription 5, 6
4. Pregnancy Status
- Must be excluded in women of childbearing potential
- This is a standard safety check for any new medication prescription
The Clinical Inertia Problem
Research reveals that clinical inertia is the most common reason (31.9%) for failing to prescribe SGLT2i in eligible patients 5. This same inertia likely explains failure to perform pre-prescription assessments. The evidence shows:
- Only 58.9% of eligible diabetic kidney disease patients receive SGLT2i despite clear indications 5
- Prescribers cite unfamiliarity with newer agents and difficulty keeping pace with evidence 7
- Primary care prescribers are less likely than specialists to consider infection history (22.2% vs 85.7%) 3
System-Level Contributing Factors
While the prescribing clinician bears primary responsibility, several system factors may have contributed 7:
- Lack of clinic-embedded pharmacist support (pharmacists significantly improve appropriate prescribing) 3, 6
- Restrictive formularies and prescribing budgets
- Inadequate dissemination of trial data and guideline updates
- Deferred initiation when specialist support is accessible
The Specific Failure
The prescribing clinician committed a compound error by failing to:
- Assess baseline kidney function before initiating therapy
- Measure albuminuria for proper risk stratification
- Screen for infection risk factors
- Verify pregnancy status
This represents a deviation from the 2024 BMJ guideline requirement that "clinicians must appropriately identify adults with CKD, consider the underlying aetiology, and risk stratify them based on glomerular filtration rate (estimated or measured) and degree of albuminuria" 1.
Preventing Future Errors
Implement a mandatory pre-prescription checklist requiring documentation of:
- eGFR value and date
- Urine ACR value and date
- Infection history screening
- Pregnancy test/contraception status
Pharmacist-led medication reviews increase appropriate SGLT2i prescribing from 40.9% to 62.7% 6, suggesting that clinical pharmacist involvement could have prevented this error.